For example, Ivonescimab (AK112, PD-1 + VEGF) combines vascular endothelial growth factor (VEGF) blockade in the TME with PD-1 immunomodulation, and demonstrates enhanced activity in NSCLC [194]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.